Small-cap pharma stock Sigachi Industries jumps after CARE reaffirms credit rating

Small-cap pharma stock Sigachi Industries gained over 2 per cent in intra-day trade on Friday, January 3, after CARE Ratings reaffirmed its rating action on the company.

In an exchange filing on Friday, the company informed that CARE Ratings Limited reaffirmed its rating on the long-term and short-term bank facilities. CARE has assigned CARE A-; Stable to Rs 75.38 crore long-term bank facilities and CARE A-; Stable / CARE A2 to Rs 51.75 crore long-term / short-term bank facilities, respectively.

The rating agency reaffirmed its action following recent developments, including the operational and financial performance of the Sigachi Industries for FY24 and H1-FY25, and the possible impact of the same on the credit profile of your company, CARE said.

Stock Impact

Sigachi Industries, part of the BSE Smallcap index, witnessed a 2.02 per cent increase in its share price to Rs 51.49 apiece.

Sigachi Industries share price opened at ₹50.48, slightly higher than the previous close of Rs 50.47 apiece. It then extended gains to hit the day’s high of Rs 51.49.

Despite today’s gains, Sigachi Industries have fared poorly in the last one year, eroding investor wealth by 14 per cent. Even in the last one month alone, the stock has lost 5 per cent.

Sigachi Industries stock is almost 90 per cent away from its 52-week high of Rs 95.94 touched in February 2024.

For the second quarter of the financial year 2024-25 (Q2FY25), the company witnessed a 38.10 per cent year-on-year rise in revenue from operations to Rs 137 crore while its profit after tax (PAT) jumped 39% YoY to Rs 21 crore.

The earnings before interest, tax, depreciation and amortisation (Ebitda) margins witnessed a 19 bps growth YoY to 21.38 per cent while PAT margins improved by 159 bps to 16.81%.

Incorporated in 1989, Sigachi Industries operates in the pharmaceutical industry, with a presence in Active Pharmaceutical Ingredients (APIs), Food and Nutrition, Operations & Management, and the Personal Care industry.

Related Posts

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

New Delhi: AstraZeneca’s India-arm has partnered with National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, to build clinical research capabilities at 25 emerging geographies in a bid to extend…

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

Following a bumpy regulatory road that involved a refusal-to-file, ImmunityBio has won FDA approval to expand Anktiva into papillary-only non-muscle-invasive bladder cancer (NMIBC). Wednesday’s approval comes nearly three months ahead…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

‘Bone Bonding’ between Mothers and Children, thanks to Meticulous Bone Grafting

‘Bone Bonding’ between Mothers and Children, thanks to Meticulous Bone Grafting

Governments have moved for Price Transparency in Hospitals to help patients cope with bills

Governments have moved for Price Transparency in Hospitals to help patients cope with bills

The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction

The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction